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R E V I E W
A R T I C L E
The Role of High Frequency Ultrasound in
Multimodality Small Animal Imaging for
Cancer Research
Ai-Ho Liao1, Pai-Chi Li1,2*
Small-animal models are extensively used in disease research, genomics research, drug
development, and developmental biology. The development of noninvasive small-animal
imaging techniques with adequate spatial resolution and sensitivity is therefore of prime
important. In particular, multimodality small-animal imaging can provide complemen-
tary information. This paper presents the role of high frequency ultrasound (microUS) in
multimodality small animal imaging for cancer research and some new trends to imple-
ment microUS and small-animal positron-emission tomography (microPET) multimodal-
ity small animal imaging. The new trends of combining these two imaging systems were
extended to perform other imaging systems. Firstly, registration of microUS/microPET is
performed using a three-dimensional registration method. In addition, microUS was
combined with microPET for tumor progressive assessment. MicroUS provides ana-
tomical information which can be used for tumor volume measurements while microPET
is a functional imaging method with positron-emitting radiophamaceuticals, such as 
18F-labeled deoxyglucose, [18F]FDG. To investigate the feasibility of the functional infor-
mation provided from microUS, the contrast enhanced ultrasound (CEUS) technique 
is an alternative way to characterize three vascular contrast phases of liver focal lesions 
in a small animal. Finally, a new technique, ensemble empirical mode decomposition
(EEMD), was used for CEUS imaging improvement. Most of primary applications of the
proposed methods are applied in cancer research on small-animal models. The multi-
modality approach represents an effective tool for both drug development and cancer
research.
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Introduction
The early and accurate diagnosis of cancer improves
the prognosis for treatment. It is very important
either in chemotherapy or in radiotherapy plan-
ning. To achieve this purpose, the combination of
molecular-functional-anatomic multiple imaging
modalities provides the highest advantage of non-
invasive method because each image modality has
its own strengths and weaknesses. Depending on
this reason; combining anatomical and functional
images was obvious to physicians in the 1960s [1].
The advantage of multimodality images, such as
positron-emission tomography-computed tomog-
raphy (PET/CT) (introduced 2001) and single pho-
ton emission computed tomography-computed
tomography (SPECT/CT) (introduced 2004) is that
the CT can be used to adjust the functional images
(PET and SPECT) for attenuation [2,3] and scatter
[4]. Thus, the progression of multimodality image
technique is rapidly and widely applied for oncology.
In 2006, there were about 21 million SPECT studies
performed in ultrasound (US) compared with 1.5
million PET and PET/CT studies [5]. However, for
PET/CT or SPECT/CT, simultaneous imaging of the
anatomy and the nuclear medicine distribution cov-
ering the same region of the patient is not possible.
On the other hand, magnetic resonance imaging
(MRI)/PET for the brain allows simultaneous acqui-
sition of both modalities, potentially creating new
research applications for neuro imaging. Recently,
whole body MRI/PET and PET/US for breast imag-
ing have extended the range of clinical multi-
modality technology [5].
Small-animal positron-emission tomography
(microPET and microcomputed tomography
(microCT) have become essential tools for evaluat-
ing new therapeutic approaches in animal models
of human disease [6]. However, combining of ultra-
sound with other imaging systems is not commonly
discussed. Ultrasound can provide the structure
and the microcirculation information for the thera-
peutic effects of cancer. In this paper, microUS 
and microPET multimodality imaging is demon-
strated as an alternative method which can provide
complementary information. The new trends and
the role of microUS in multimodality small animal
imaging for cancer research are discussed in this
paper.
High frequency ultrasound is refers to the fre-
quency range above 20 MHz [7–9]. MicroUS is an
important tool for obtaining non-invasive real-time
images of small animals. A spatial resolution of less
than 100μm can be achieved if high-frequency ultra-
sound is used. PET provides three dimensional (3D)
distribution of positron-emitting radiopharmaceu-
ticals. Using radiolabeled biomolecules and kinetics
models, PET can be utilized for quantitative mea-
surements of many metabolic functions in living
animals, such as in the brain, heart or in tumors. For
small animal studies, microPET [10,11] was designed
with an improved spatial resolution over clinical PET.
The spatial resolution of microPET (R4, Concord
Microsystems, Knoxville, TN, USA) was about 1.8mm
at the center of the field of view and dropped to
2.5 mm (radial component) at 25 mm off-center
[12]. Our previous studies showed that the real-
time anatomical information with high-resolution
combined with functional information can be ob-
tained simultaneously by integrating microUS and
microPET systems.
An effective registration method is necessary since
it is difficult to perform both imaging procedures
simultaneously with a known geometrical relation-
ship between them. Nevertheless, the imaging pro-
cess is more limited in high resolution small animal
imaging systems than in clinical imaging systems.
MicroUS and microPET were performed in a mouse
tumor longitudinal study (2–8 weeks), both with
3D tumor segmentation and volume measurements.
To investigate the effectiveness of the microUS func-
tional imaging, the contrast enhanced microUS
tumor imaging was used to detect three vascular
contrast phases and characterize malignant focal
liver lesions. Contrast enhanced ultrasound (CEUS)
imaging has been a reliable clinical method of detect-
ing three vascular contrast phases and characteriz-
ing focal liver lesions. Ultrasound contrast agents
strongly increase the ultrasound backscatter and
therefore are useful in the enhancement of blood
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echogenicity for the assessment of blood flow in
the vasculature, however all of these studies have
been performed in humans and not small animals
[13–18]. CEUS are generally based on the cancella-
tion and/or separation of linear ultrasound signals
from tissue and utilization of the nonlinear response
from microbubbles [19–22]. Recently, the Hilbert-
Huang transform (HHT), first introduced by Huang
et al in 1998 [23], has been used extensively in the
analysis of nonlinear and non-stationary signals.
This paper also demonstrates the contrasting im-
provement in ultrasound nonlinear imaging using
a new ensemble empirical mode decomposition of
HHT. The application of the new technique was
expected to enhance the effectiveness of CEUS in
tumor imaging.
Registration Method for MicroUS/
MicroPET Multimodality Small-Animal
Imaging
Image registration is the most significant move
towards the combination of various image modal-
ities. Medical image registration could involve the
spatial and temporal relationship among all the
available image information [24]. The majority 
of the registration methods consist of landmark-
based registration, surface-based registration, and
point intensity similarity measured-based registra-
tion. The transformation methods consist of rigid
body transformation and non-rigid body transfor-
mation [25–27]. Most medical image registration
algorithms additionally assume that the transforma-
tion is rigid body. However, the ultrasound images
are acquired with a free-hand transducer. The trans-
ducer must be moved in a controlled way, and a
three-dimensional dataset obtained for 3D image
registration [28].
Previous studies employed a rigid-body transfor-
mation [29] combined with a microUS/microPET
multimodality phantom containing six image mark-
ers. A registration phantom with six markers was
designed so that it could be placed in a small-animal
holder. The procedure for constructing the registra-
tion phantoms is outlined in Fig. 1. The phantom
was made with 2% agarose solution. To prepare the
alignment markers, six glass beads with a diameter
of 0.43–0.60 mm were placed individually inside
six holes created in the phantom. The holes were
created with a diameter of 1 mm and the length of
the column was around 3 mm. The six markers were
Time
1. The
registration
phantom with
six holes was
put into the
small animal
holder
2. Inject [18F]FDG
into tumor-
bearing mice
3. Each hole was
injected with
0.1 μL [18F]FDG
(about 0.2 μCi)
7. Six holes were filled with agarose
solution, the animal holder was filled
with water for microUS
2. 425–600
μm glass
beads were
put into each
hole
separately
5. The tumor
bearing mouse
was fixed
6. MicroPET
 imaging
3 hr 30 min 10 min 15 min
Fig. 1. Photograph and flow chart of the procedure for constructing the registration phantom and the small-animal holder. 
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positioned around the tumor surface at 4–5 mm dis-
tances. In addition, 0.1 μL of [18F]FDG was injected
into each hole using a microinjector, and the WF-3
ovarian tumor-bearing mouse was then fixed in
the holder with the registration phantom. The tumor
was implanted subcutaneously on the right shoul-
der of the C57BL/6J black mouse for 2 weeks [30].
After image reconstruction, the boundaries of the
six markers were contoured and the center of gravity
of each marker was calculated, and then the center
of gravity of the six markers was used to perform
the rigid-body registration transformation. These six
markers were matched in the microUS and microPET
images by using three image processing steps: (1)
making the voxel size the same in the two imaging
systems, (2) rigid-body image registration, and 
(3) fusing the images from the two systems.
Evaluation of the image registration accuracy is
necessary because the errors can be dragged into
the registration process. The orthogonal Procrustes
algorithm [31] was normally used for a rigid-body
transformation, and the fiducial registration error
(FRE) and the target registration error (TRE) was used
to quantify the registration precision. In the microUS/
microPET registration system, the FRE ranged from
0.12 to 0.58 mm, with a mean of 0.31 mm [29].
The mean FRE and TRE of three registration phan-
toms are 0.68 and 1.05 mm, respectively [29]. TRE
is generally larger than FRE, because the registration
is performed based on the markers rather than the
target. The registration precision is superior than
microPET image resolution while inferior to microUS
image resolution. Fig. 2 shows microUS/microPET
fused (a) transverse, (b) sagittal, and (c) coronal
views of a second-week tumor with registration
markers. The microUS provides the tumor structure
information with a gray map and microPET shows
the radiopharmaceutical metabolism within the
tumor region with a color map.
Noninvasive Tumor Imaging with
MicroUS and MicroPET in Small 
Animals
The characteristics of microUS and microPET are
presented in Table 1 [32,33]. MicroPET imaging
allows for both the temporal and the spatial bio-
distribution of a molecular probe to be determined
in a single living animal model. [18F]FDG, a PET
reporter probe, is able to provide both functional
and metabolic information for the process of tumor
growth in oncology [34]. However, a PET cyclotron
is required to produce radioisotopes. The radiation
has to be carefully shielded. The real-time nature of
microUS on the other hand, is facilitating in ana-
tomical and hemodynamic studies on small animals,
such as mouse embryonic development, in vivo
transgenic mouse disease models, and image-
guided interventions on mice [7–9].
3D microUS imaging and segmentation were
reported and shown to be a reliable tool in the
early detection and longitudinal growth analysis 
of xenograft tumors in mice [35]. MicroUS and
A B C
Fig. 2. MicroUS and microPET fused  to create a 3D image. (A) transverse, (B) sagittal, and (C) coronal images of the tumor
region with the registration markers.
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[18F]FDG microPET imaging were also performed
on C57BL/6J black mice bearing WF-3 ovarian car-
cinoma on a weekly basis. For each mouse, tumor
growth was monitored in vivo by traditional caliper
measurement, microUS and [18F]FDG microPET.
3D tumor segmentation and volume estimation
were applied to tumors from 2 to 8 weeks after
tumor implantation. The comparison between the
three modalities was performed [36].
The working flow chart of designing microUS/
microPET multimodality imaging for cancer research
is outlined in Fig. 3. After image registration, the
tumors in microUS 3D small-animal images were
segmented and 3D volume data were reconstructed.
In Fig. 4A, a tumor was removed from a mouse in
the 8th week after tumor implantation. MicroPET 
in vivo image (partial transverse section), tumor seg-
mentation, and the corresponding 3D representa-
tion of the 8th-week tumor are shown in Fig. 4B.
Fig. 4C shows a B-mode microUS in vivo image
(partial transverse section), tumor segmentation,
and the corresponding 3D representation in the
8th week. Fig. 4D shows a microUS/microPET fused
image (after registration), tumor segmentation, and
the corresponding 3D representation of the 8th-
week tumor. The caliper measurement, microUS and
microPET imaging data are compared for tumor
growth study. The ratios of tumor volumes obtained
from week 2–4 from microUS and calipers varied
from 58–76%, but were 102–138% for microPET
[36]. Manual caliper measurements were affected
by skin layers and surrounding nontumoral tissue,
leading to an overestimation of tumor size. None-
theless, the tumor volumes obtained from microPET
imaging were even larger due to its insufficient spa-
tial resolution. The over-estimation was primarily
due to inadequate spatial resolution. In other words,
the large extent of the point spread function of the
imaging system caused the over-estimation. These
results suggest that microUS is more reliable than
microPET for tumor volume measurements at early
stages. Moreover, in the late stages (5–8 weeks),
standard deviations of microPET tumor volume
measurements were large. The tumor boundary 
in microPET imaging is generally not clear after Ta
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A B
DC
Fig. 4. (A) Parenchyma of a tumor in the 8th week following a tumor implantation. (B) MicroPET image (partial transverse 
section), tumor segmentation, and the corresponding 3D representation of the 8th-week tumor. (C) B-mode microUS image (par-
tial transverse section), tumor segmentation, and the corresponding 3D representation in the 8th week. (D) MicroUS/microPET
fused image (after registration), tumor segmentation, and the corresponding 3D representation in the 8th-week tumor.
Data acquisition:
High frequency ultrasound and microPET imaging
Registration:
Phantom design and rigid body transformation
Tumor segmentation and 3D reconstruction
Data analysis and imaging improvement Multimodality imaging in cancer
Image fusion
Image reconstruction:
• B-mode and color doppler imaging
• Filtering book projection imaging and radiopharmacokinetic studies
Small animal studies:
• Tumor growth
• Contrast enhanced ultrasound
Fig. 3. Working flow chart of designing microUS/microPET multimodality imaging for cancer research.
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5 weeks, possibly due to hypoxia and/or necrosis
when the tumor grows bigger. The hypoxic or
necrotic tumor areas do not uptake radiopharma-
ceuticals, thus making it difficult to define the 
contour in microPET imaging [37].
Characterization of Focal Liver Lesions
in Mice with 40 MHz CEUS Techniques 
In Fig. 3, for small animal study, CEUS imaging can
evaluate tumor angiogenesis. Hepatocellular carci-
noma (HCC) is a primary liver malignancy which
mostly occurs in association with cirrhosis or chronic
hepatitis in humans [14–19]. CEUS imaging plays
an important role in the clinical diagnosis of this
disease, providing information on the hemody-
namic changes of the HCC and aiding detection of
the blood supply peculiar to HCC. Previous studies
have found that HCC can be characterized by
rapid intensity enhancement in the arterial phase
(10–35 seconds after contrast injection), a rapid
washout in the portal phase (30–120 seconds after
contrast injection), and intensity enhancement of
liver parenchyma in the parenchyma phase (120–
360 seconds after contrast injection) [14–19]. 
A non-linear response from microbubbles is
based on two different mechanisms [20–23]: one
is a non-linear response from microbubble oscilla-
tions at low acoustic pressure, and the other is a
high energy broadband non-linear response aris-
ing from microbubble disruption. In a previous study,
the albumin-shelled microbubbles were used as the
contrast agent and ultrasound B-mode imaging
was done at low MI (0.188). In preclinical mouse
liver metastasis models, high-frequency ultrasound
imaging has been used to measure the tumor vol-
ume, assess metastatic progression, and evaluate
chemotherapeutics [38,39]. In a previous study, the
imaging system and contrast agent were used to
characterize three vascular contrast phases of focal
liver lesions in Hepatitis B virus X (HBx) transgenic
mice. The results were arranged according to the
guidelines of European Federation of Societies for
Ultrasound in Medicine and Biology (EFSUMB) [40]
and histopathology findings. The typical enhance-
ment patterns of benign lesions are summarized in
Table 2 for the following lesions: haemangioma,
FNH, focal fatty sparing, focal fatty change, regen-
erative nodules, cysts, adenoma, and abscesses
[40]. The enhancement patterns for the character-
ization of malignant lesions (HCC, hypovascular
metastases, hypervascular metastases, cholangio
carcinoma) are summarized in Table 3 [40].
Vascular phases in CEUS of the mice liver are
arranged in Table 4 [41]. In Table 4, the arterial
phase ranges from 2 to 60 seconds post contrast
injection. The time period from 10 to 30 minutes
post contrast injection was defined as the paren-
chyma phase in this study. The pathology was
characterized as a gold standard by a pathologist.
The imaging results were compared with the pathol-
ogy results, the sensitivity, specificity and accuracy
of CEUS for the detection of malignant focal liver
lesions in HBx transgenic mice were 91%, 100%
and 92%, respectively. Fig. 5A shows the hypovas-
cular metastases lesion in a mouse before contrast
injection. In Fig. 5B, the hyper-enhancing feature
was shown during the arterial phase. The hypo-
enhancing feature at 30 minutes after contrast
injection is shown in Fig. 5C. The tumor entity was
defined as the hypovascular metastases lesion by
the image properties and histology (Fig. 5D).
Contrast Improvement in Ultrasound
Nonlinear Imaging Using Ensemble
Empirical Mode Decomposition (EEMD) 
For the data analysis and imaging improvement
(Fig. 3), ultrasound harmonic imaging with contrast
agents takes advantage of the nonlinear response
of the contrast agent. However, the contrast-to-
tissue ratio (CTR) is still limited because significant
harmonic echoes are also present in surrounding
tissues. Instead of conventional filtering, the pulse
inversion (PI) technique is an alternative method to
extract the contrast harmonic signal [42–44]. HHT
has recently been applied as an innovative signal
processing technique in many diverse applications
Multimodality Small Animal Tumor Imaging
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with success. It is a data analysis designed specifi-
cally for analyzing nonlinear and non-stationary
signals. Empirical mode decomposition (EMD) is
the key part of HHT proposed as an adaptive
time–frequency analysis method for nonlinear and
non-stationary data. A new EEMD method consists
of an ensemble of decompositions of data with
added white noise, and then treats the resultant
mean as the final true result [45]. Compared to the
contrast detection with fundamental and second
harmonic imaging obtained using PI based nonlin-
ear imaging, the CTRs in fundamental and second
harmonic bands are improved by 9.9 and 4.2 dB
after EEMD [46].
Discussion and Conclusions
The combing methods of microUS and microPET
multimodality imaging systems could be extended
to integrate other imaging systems into these new
techniques. For example, the homemade microbub-
bles could be generated as a multimodality con-
trast agent. The homemade ultrasound contrast
Table 2. Enhancement patterns of benign focal liver lesions in a human
Tumor entity Arterial phase PV phase Delayed phase
Hemangioma
Typical features Peripheral-nodular E, Partial/complete Complete E 
no central E, rim E centripetal filling
Additional features Small lesion: complete, Non-enhancing central 
rapid centripetal E areas (partial thrombosis, 
fibrosis)
FNH
Typical features Hyper-enhancing, Hyper-enhancing Iso-, hyper-enhancing
complete, early
Additional features Spoke wheel arteries, Hypo-enhancing Hypo-enhancing central 
centripetal filling, central scar scar
feeding artery
Focal fatty sparing
Typical features Iso-enhancing Iso-enhancing Iso-enhancing
Focal fatty change
Typical features Iso-enhancing Iso-enhancing Iso-enhancing
Regenerative nodule
Typical features Iso-enhancing Iso-enhancing Iso-enhancing
Additional features Hypo- or hyper-enhancing
Cyst
Typical features Non-enhancing Non-enhancing Non-enhancing
Adenoma
Typical features Hyper-enhancing, complete Iso-enhancing Iso-enhancing
Additional features Non-enhancing areas Hyper-enhancing, Non-enhancing areas 
(hemorrhage) non-enhancing areas (hemorrhage)
(hemorrhage)
Abscess
Typical features No central E, rim E Hyper-/iso-enhancing Hypo-enhancing rim, 
rim, no central E no central E
Additional features Enhanced septa, hyper- Hypo-enhancing rim,
enhanced liver segment enhanced septa
E = enhancement.
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agent used in this study comprised microbubbles
with albumin shells, and is similar to the commercial
ultrasound contrast media Optison™ (GE Healthcare,
Bucks, United Kingdom) [47,48]. The number of the
homemade albumin-based microbubbles in each
solution was measured with MultiSizer III (Beckman
Coulter, USA) with a 30 μm aperture probe, whose
measurement boundary is between 0.6–20 μm. The
concentration of the microbubbles ranges from
4.24–8.43 × 108/mL. The mean diameter number
size is 0.7–2.0 μm. A multiplicity of ligands may be
coupled to microbubbles directly via covalent bonds
or indirectly through avidin-biotin interactions. Ultra-
sonically reflective albumin particles can be attached
to [18F]SFB for PET, paramagnetics for MRI, D-luciferin
for bioluminescence, or fluorescence for microscope
multimodal imaging.
The primary application of the proposed method
is in cancer research on small-animal models. In such
applications, microUS provides excellent anatomical
information, whereas microPET provides informa-
tion on glucose metabolism. Future studies could add
CEUS imaging to evaluate the vascular phase in tu-
mors. Since cancer drugs are delivered to the tumors
via the vessels, such a multimodality approach rep-
resents an effective tool for both drug develop-
ment and cancer research. In conclusion, microUS
and microPET imaging techniques were applied
for evaluating the tumor growth and progression.
The results suggest that microUS is more reliable
than microPET and traditional calipers in tumor
volume analysis, especially when tumor volume is
small. When the tumor is in its late stages, tumor
hypoxia and necrosis can be detected by microPET.
Table 3. Enhancement patterns of malignant focal liver lesions in a human
Tumor entity Arterial phase PV phase Delayed phase
HCC
Typical features Hyper-enhancing, complete Iso-, hypo-enhancing Hypo-enhancing
non-enhancing areas (necrosis) non-enhancing areas 
Additional features “Chaotic” vessels, enhancing (necrosis)
tumor thrombus in 
PV + HCC/portal vein
Hypovascular mets
Typical features Rim E Hypo-enhancing Hypo-, non-enhancing
Additional features Complete E, non-enhancing areas Non-enhancing areas 
(necrosis) (necrosis)
Hypervascular mets
Typical features Hyper-enhancing, complete Hypo-enhancing Hypo-, non-enhancing
Additional features “chaotic” vessels
Cholangio carcinoma
Typical features Rim E Hypo-, non-enhancing Hypo-, non-enhancing
Additional features Non-enhancing
E = enhancement.
Table 4. Three vascular phases in contrast enhanced ultrasound of the liver in HBx transgenic mice
Phase
Visualization post-injection 
End
time (sec) start
Arterial 2–14 21–60s
Portal-venous 21–60 600 (10 min)
Late 600 (10 min) The decay of parenchyma enhancement
(approx. after 1800 [30 min])
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The combination of the anatomical information
obtained from microUS and the metabolism infor-
mation from microPET imaging, can be a valuable
tool in cancer research. Image registration and fusion
methods are being developed as the next step in
realizing the potential of microUS/microPET multi-
modality imaging. Contrast-enhanced 40 MHz
ultrasound imaging enhances the ability to detect
three vascular phases and characterize malignant
focal lesions, and would provide more information
during experimental HCC treatments in small 
animal models. Moreover, the EEMD method for
contrast improvement in ultrasound nonlinear
imaging can help to develop the effectiveness of
CEUS imaging.
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